Last reviewed · How we verify

Dibazol — Competitive Intelligence Brief

Dibazol (BENDAZOL) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: bendazol. Area: Cardiovascular.

phase 2 bendazol Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dibazol (BENDAZOL). Dibazol works by interacting with a specific biological target to produce a therapeutic effect.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dibazol TARGET BENDAZOL phase 2 bendazol
Ricobendazole albendazole sulfoxide marketed albendazole sulfoxide Tubulin alpha chain
Febendazole FENBENDAZOLE marketed fenbendazole Mitogen-activated protein kinase 14, Beta-lactamase 1
Flumoxane FLUBENDAZOLE marketed flubendazole

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (bendazol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dibazol — Competitive Intelligence Brief. https://druglandscape.com/ci/bendazol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing